319 related articles for article (PubMed ID: 19387108)
1. Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis.
Lyn-Cook LE; Lawton M; Tong M; Silbermann E; Longato L; Jiao P; Mark P; Wands JR; Xu H; de la Monte SM
J Alzheimers Dis; 2009; 16(4):715-29. PubMed ID: 19387108
[TBL] [Abstract][Full Text] [Related]
2. Ceramide-mediated insulin resistance and impairment of cognitive-motor functions.
de la Monte SM; Tong M; Nguyen V; Setshedi M; Longato L; Wands JR
J Alzheimers Dis; 2010; 21(3):967-84. PubMed ID: 20693650
[TBL] [Abstract][Full Text] [Related]
3. Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease.
Tong M; Neusner A; Longato L; Lawton M; Wands JR; de la Monte SM
J Alzheimers Dis; 2009; 17(4):827-44. PubMed ID: 20387270
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of ceramide-mediated neurodegeneration.
Tong M; de la Monte SM
J Alzheimers Dis; 2009; 16(4):705-14. PubMed ID: 19387107
[TBL] [Abstract][Full Text] [Related]
5. Limited Alzheimer-type neurodegeneration in experimental obesity and type 2 diabetes mellitus.
Moroz N; Tong M; Longato L; Xu H; de la Monte SM
J Alzheimers Dis; 2008 Sep; 15(1):29-44. PubMed ID: 18780965
[TBL] [Abstract][Full Text] [Related]
6. Role of sphingolipid mediator ceramide in obesity and renal injury in mice fed a high-fat diet.
Boini KM; Zhang C; Xia M; Poklis JL; Li PL
J Pharmacol Exp Ther; 2010 Sep; 334(3):839-46. PubMed ID: 20543095
[TBL] [Abstract][Full Text] [Related]
7. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.
de la Monte SM; Longato L; Tong M; Wands JR
Curr Opin Investig Drugs; 2009 Oct; 10(10):1049-60. PubMed ID: 19777393
[TBL] [Abstract][Full Text] [Related]
8. ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis.
Fucho R; Martínez L; Baulies A; Torres S; Tarrats N; Fernandez A; Ribas V; Astudillo AM; Balsinde J; Garcia-Rovés P; Elena M; Bergheim I; Lotersztajn S; Trautwein C; Appelqvist H; Paton AW; Paton JC; Czaja MJ; Kaplowitz N; Fernandez-Checa JC; García-Ruiz C
J Hepatol; 2014 Nov; 61(5):1126-34. PubMed ID: 24946279
[TBL] [Abstract][Full Text] [Related]
9. Nitrosamine exposure exacerbates high fat diet-mediated type 2 diabetes mellitus, non-alcoholic steatohepatitis, and neurodegeneration with cognitive impairment.
de la Monte SM; Tong M; Lawton M; Longato L
Mol Neurodegener; 2009 Dec; 4():54. PubMed ID: 20034403
[TBL] [Abstract][Full Text] [Related]
10. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides.
Cinar R; Godlewski G; Liu J; Tam J; Jourdan T; Mukhopadhyay B; Harvey-White J; Kunos G
Hepatology; 2014 Jan; 59(1):143-53. PubMed ID: 23832510
[TBL] [Abstract][Full Text] [Related]
11. Protection from high fat diet-induced increase in ceramide in mice lacking plasminogen activator inhibitor 1.
Shah C; Yang G; Lee I; Bielawski J; Hannun YA; Samad F
J Biol Chem; 2008 May; 283(20):13538-48. PubMed ID: 18359942
[TBL] [Abstract][Full Text] [Related]
12. The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur S; Brunner B; Bielohuby M; Hansen G; Pfenninger A; Wang B; Bruning JC; Larsen PJ; Tennagels N
Mol Metab; 2019 Mar; 21():36-50. PubMed ID: 30655217
[TBL] [Abstract][Full Text] [Related]
13. Diabetes is a progression factor for hepatic fibrosis in a high fat fed mouse obesity model of non-alcoholic steatohepatitis.
Lo L; McLennan SV; Williams PF; Bonner J; Chowdhury S; McCaughan GW; Gorrell MD; Yue DK; Twigg SM
J Hepatol; 2011 Aug; 55(2):435-44. PubMed ID: 21184785
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption.
Ussher JR; Koves TR; Cadete VJ; Zhang L; Jaswal JS; Swyrd SJ; Lopaschuk DG; Proctor SD; Keung W; Muoio DM; Lopaschuk GD
Diabetes; 2010 Oct; 59(10):2453-64. PubMed ID: 20522596
[TBL] [Abstract][Full Text] [Related]
15. Early limited nitrosamine exposures exacerbate high fat diet-mediated type 2 diabetes and neurodegeneration.
Tong M; Longato L; de la Monte SM
BMC Endocr Disord; 2010 Mar; 10():4. PubMed ID: 20302640
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of serine palmitoyl transferase I reduces cardiac ceramide levels and increases glycolysis rates following diet-induced insulin resistance.
Ussher JR; Folmes CD; Keung W; Fillmore N; Jaswal JS; Cadete VJ; Beker DL; Lam VH; Zhang L; Lopaschuk GD
PLoS One; 2012; 7(5):e37703. PubMed ID: 22629445
[TBL] [Abstract][Full Text] [Related]
17. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis.
Ota T; Takamura T; Kurita S; Matsuzawa N; Kita Y; Uno M; Akahori H; Misu H; Sakurai M; Zen Y; Nakanuma Y; Kaneko S
Gastroenterology; 2007 Jan; 132(1):282-93. PubMed ID: 17241878
[TBL] [Abstract][Full Text] [Related]
19. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes.
Mitsutake S; Zama K; Yokota H; Yoshida T; Tanaka M; Mitsui M; Ikawa M; Okabe M; Tanaka Y; Yamashita T; Takemoto H; Okazaki T; Watanabe K; Igarashi Y
J Biol Chem; 2011 Aug; 286(32):28544-55. PubMed ID: 21669879
[TBL] [Abstract][Full Text] [Related]
20. The sphingosine-1-phosphate analog FTY720 reduces muscle ceramide content and improves glucose tolerance in high fat-fed male mice.
Bruce CR; Risis S; Babb JR; Yang C; Lee-Young RS; Henstridge DC; Febbraio MA
Endocrinology; 2013 Jan; 154(1):65-76. PubMed ID: 23183172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
